Culper Research’s short report accusing ADMA Biologics (ADMA) of inflating revenue by encouraging a distributor to hold excess stock has triggered securities fraud investigations and multiple class action efforts, putting the company’s reported growth and guidance under scrutiny.

At a share price of US$8.56, ADMA’s recent legal headlines have coincided with sharp share price pressure, including a 30 day share price return down 21.32% and a 90 day share price return down 47.55%, even though the three year total shareholder return is up 112.41% and the five year total shareholder return is up about four times.

If this kind of volatility has you looking beyond a single biopharma stock, it can help to scan a broader set of healthcare opportunities, including companies using AI in medicine through our 30 healthcare AI stocks

So with ADMA trading at US$8.56, recent legal pressure, a very sharp pullback, and a large gap to analyst targets on one side, is the stock now mispriced or is the market already discounting future growth?

Most Popular Narrative: 59.1% Undervalued

Compared with ADMA Biologics' last close at $8.56, the most followed narrative on Simply Wall St assigns a fair value of $20.93, implying a large valuation gap that hinges on strong profitability and cash flow expectations.

Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF, 134 MUSD, revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029, growth of 21%/year), currently undervalued

Curious what underpins that kind of upside? The narrative leans heavily on compound revenue expansion, rising margins and a future earnings multiple usually reserved for mature, high quality cash generators.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on user assumptions around ADMA reaching ambitious revenue, margin, and multiple targets, while current legal scrutiny and distributor practices could disrupt that path.

Next Steps

Given the mix of legal risk, valuation optimism, and recent volatility, you may want to review the underlying data and sentiment quickly and then shape your own view with our 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop at just one stock, you could miss opportunities that better fit your goals, so take a few minutes to scan broader ideas with the Simply Wall St screener.

• Target potential bargains by checking out 51 high quality undervalued stocks that combine quality fundamentals with prices that may not reflect their underlying strength.
• Focus on resilience first by reviewing 67 resilient stocks with low risk scores that score well on financial stability and downside protection.
• Spot under-the-radar opportunities by using the screener containing 21 high quality undiscovered gems that have solid fundamentals but limited current attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.